Advanced Multiscale Inhalation Platforms for Treatment of Pulmonary Diseases
Abstract
Pulmonary diseases, including chronic obstructive pulmonary disease, asthma, pneumonia, pulmonary fibrosis, and lung cancer, pose a significant threat to global health. Their high incidence and mortality rates highlight the urgency for novel therapeutic approaches. Traditional treatments such as oral and injection administrations face limitations like first-pass effects, low bioavailability, and systemic toxicity, which restrict their therapeutic efficacy. Inhaled preparations, with advantages such as uniform drug distribution, rapid onset, high bioavailability, and avoidance of hepatic first-pass effects, have become effective means for treating lung diseases. This article reviews the research progress of novel inhaled preparations (nanoparticles, liposomes, microspheres, biomimetic platforms) in treating lung diseases, aiming to explore the development and application of novel inhaled formulations driven by advancements in nanotechnology, biomaterials and preparation processes, thereby providing new possibilities for lung disease treatment. Overall, the research and application prospects of novel inhaled preparations are broad, promising more effective and safer treatment options for patients with pulmonary diseases.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.